KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Capital Expenditures (2016 - 2025)

Eli Lilly's Capital Expenditures history spans 17 years, with the latest figure at $2.5 billion for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 70.21% year-over-year to $2.5 billion; the TTM value through Dec 2025 reached $7.8 billion, up 55.02%, while the annual FY2025 figure was $7.8 billion, 55.02% up from the prior year.
  • Capital Expenditures reached $2.5 billion in Q4 2025 per LLY's latest filing, up from $2.1 billion in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.5 billion in Q4 2025 to a low of $291.4 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $975.6 million, with a median of $854.2 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 35.91% in 2021, then skyrocketed 113.9% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $291.4 million in 2021, then soared by 71.83% to $500.7 million in 2022, then surged by 113.9% to $1.1 billion in 2023, then skyrocketed by 39.7% to $1.5 billion in 2024, then soared by 70.21% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Capital Expenditures are $2.5 billion (Q4 2025), $2.1 billion (Q3 2025), and $1.7 billion (Q2 2025).